Corcept Therapeutics
CORT
321 hedge funds and large institutions have $4.09B invested in Corcept Therapeutics in 2024 Q3 according to their latest regulatory filings, with 63 funds opening new positions, 106 increasing their positions, 107 reducing their positions, and 26 closing their positions.
142% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 26
63% more call options, than puts
Call options by funds: $54.3M | Put options by funds: $33.3M
41% more capital invested
Capital invested by funds: $2.9B → $4.09B (+$1.19B)
40% more funds holding in top 10
Funds holding in top 10: 5 → 7 (+2)
13% more funds holding
Funds holding: 285 → 321 (+36)
1% less repeat investments, than reductions
Existing positions increased: 106 | Existing positions reduced: 107
1.06% less ownership
Funds ownership: 85.72% → 84.66% (-1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.1M |
| 2 |
Norges Bank
Oslo,
Norway
|
+$15.6M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$12.5M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.56M |
| 5 |
MGP
M&G plc
London,
United Kingdom
|
+$8.63M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$17.4M |
| 2 |
Man Group
London,
United Kingdom
|
-$17M |
| 3 |
Renaissance Technologies
New York
|
-$14.3M |
| 4 |
JAM
Jupiter Asset Management
London,
United Kingdom
|
-$10.1M |
| 5 |
Cambridge Investment Research Advisors
Fairfield,
Iowa
|
-$9.22M |
CORT Hedge Fund Activity: Q3 2024 in Review
321 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Corcept Therapeutics (CORT) for Q3 2024, worth a combined $4.09B — up 41% from $2.9B a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new CORT positions and 26 closed out — a net gain of 37 holders — while 106 added to existing stakes and 107 trimmed.
The largest buyer was Vanguard Group, adding an estimated $16.1M. The largest seller was BlackRock, cutting an estimated $17.4M.
- 321 institutional investors held Corcept Therapeutics (CORT) as of Q3 2024, up from 285 in Q2 2024.
- Funds reported $4.09B of Corcept Therapeutics stock for Q3 2024, up 41% quarter-over-quarter.
- 63 funds opened new Corcept Therapeutics positions in Q3 2024 and 26 closed out, a net change of +37 holders.
- The largest Corcept Therapeutics buyer in Q3 2024 was Vanguard Group, an estimated $16.1M added.
- The largest Corcept Therapeutics seller in Q3 2024 was BlackRock, an estimated $17.4M sold.
Based on aggregated 13F filings for Q3 2024.